
CATalyst Council Launches Landmark 40,000 Household Pet Ownership Study Focused on Advancing Feline Health
"This study will arm the industry with the data to bend the curve by taking real, measurable steps toward solving the feline care gap." -Jon Ayers, CATalyst Council, Feline Market Insights Committee Chair Share
Designed by CATalyst with support of key industry association collaborators and two leading animal health market research firms, Forward Group and Kynetec, this initiative is one of the most comprehensive studies of U.S. household pet ownership ever undertaken, and the largest in the last five years. This primary consumer research builds on the momentum of the CATalyst Council's quarterly Feline Market Insights Reports, a series of analyses launched in early 2025 to track feline and overall visit trends and drivers, demographic shifts, and caregiver mindsets.
'The quarterly market insight reports reveal critical trends in veterinary health and also help us frame the questions of pet owners,' said Jon Ayers, CATalyst Council board member and chair of its Market Insights Committee. 'Now we will have it straight from the pet owner. The survey results will also give the industry and profession the most definitive view of pet ownership in the US, including the demographic age profile for both cats and dogs. This knowledge of pet demographics is destiny: the age profiles help predict future veterinarian visit growth. We will also come to understand vet visit behavior by pet and owner demographic. And thus, this study will arm the industry with the data to bend the curve by taking real, measurable steps toward solving the feline care gap."
'This is about listening to the households that shape our profession's future,' said Dr. Anne Ward, Chair of CATalyst Council. 'To be truly cat friendly every day, we must understand the human behaviors, perceptions, and emotional motivators that surround feline care, and we're doing it at a scale that's never been done before.'
'For too long, we've made assumptions about why cats don't get the care they need,' said Dr. Jane Brunt, Executive Director of CATalyst Council. 'This consumer research replaces assumptions with evidence, so we can build better solutions for cats, their people, and the professionals who care for them.'
'CATalyst is grateful for the technical support and advice we are receiving from our industry and association collaborators, including FelineVMA, AVMA, and APPA, as well as our leading industry sponsors,' said Brunt.
While this landmark survey will also capture dog ownership and veterinary visit behaviors in order to establish key industry benchmarks, the core focus is on understanding the full spectrum of behaviors, beliefs, and barriers among cat-owning households nationwide.
A Strategic Roadmap: From Market Signals to Measurable Change
Building on the foundation laid by CATalyst Council's Feline Market Insights Reports, the survey will deepen understanding of what motivates or prevents cat owners from seeking care, how generational mindsets shape veterinary decisions, and what emerging patterns can guide future innovation across veterinary medicine, the animal health industry, and aligned pet care brands.
Research Objectives
Aligned with CATalyst Council's mission to improve the lives of cats and their people through innovation, education, and appropriate medicalization, the study aims to:
Provide an updated and statistically robust estimate of cat and dog populations in U.S. households, and by year of age
Reveal emotional, psychological, and behavioral drivers of veterinary visit behavior and avoidance
Identify motivators that can increase feline medicalization, especially in multi-pet households
Inform the development of tools, education, and strategies to support industry-wide progress
Designed for Impact, Built for the Entire Ecosystem
This research is structured to deliver value across the feline care ecosystem:
Cat Owners & Caregivers: Insights into how and why caregivers seek (or delay) veterinary care
Veterinary Teams: Actionable findings to support client communication, adherence, and visit growth
Animal Health and Pet Care Companies: Data to support product innovation, education programs, and marketing strategy
Investors: Clear visibility into the drivers behind veterinary visits, trends, as well as emerging opportunities in the growing market for feline veterinary care
Initial findings will begin rolling out in Q4 2025, with detailed insights shared exclusively with our CATalyst sponsors and strategic partners. The study, along with CATalyst's quarterly reports, will empower industry and veterinary professionals to pilot targeted programs and measure impact based on validated feline and caregiver needs, ensuring the industry stays informed, aligned, and equipped to act.
'As we honor International Cat Day, we're focused not just on celebrating cats, but on understanding them, supporting their people, and building the systems that can serve them both better,' said Kristin Wuhrman, Vice Chair of the CATalyst Council. 'This is much more than the research. It's infrastructure for the future of feline care.'
To receive updates or inquire about the benefits of sponsorship, please visit catalystcouncil.org and follow CATalyst Council on LinkedIn.
About CATalyst Council
CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst Council's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers
MARSHALL, Texas--(BUSINESS WIRE)--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. Texas is intervening in the litigation as a plaintiff with the Health Choice Alliance, a research organization jointly represented by The Lanier Law Firm and McKool Smith PC. The lawsuit, filed in Harrison County, accuses Eli Lilly of offering the kickbacks to steer providers to write prescriptions for as many as 14 high-demand drugs such as the GLP-1 medications Mounjaro and Zepbound, resulting in millions of dollars in claims to the state's Medicaid program. Because those charges resulted from Eli Lilly's suspect marketing and service arrangements, the lawsuit claims the practice violated the Texas Health Care Program Fraud Prevention Act and Texas Anti-Kickback Statute. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. 'As a result, Texas Medicaid became responsible for millions of dollars in improper payments. This case should serve as a warning to the other pharmaceutical giants that such unlawful activities will be investigated and prosecuted.' The lawsuit states that the company provided free nursing services to patients who were prescribed Eli Lilly drugs and offered a supposedly independent web-based service that was in fact managed by Eli Lilly to direct patients to the desired drugs. In addition, the kickbacks involved free services to physicians to obtain insurance authorizations and authorization from Texas Medicaid on behalf of patients, a time-consuming process with administrative costs that are not normally reimbursable to the provider. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' The case is Texas vs. Eli Lilly & Co Inc., filed in the 71st District Court of Harrison County, Texas. About The Lanier Law Firm For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 50 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, and Los Angeles.


Business Wire
3 hours ago
- Business Wire
CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells
BOSTON--(BUSINESS WIRE)-- CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to advance the development of its proprietary CIL-Key™ platform — a novel, gene-agnostic delivery technology that significantly and reproducibly enhances the transfection efficiency and delivery of inhaled RNA-loaded lipid nanoparticles (RNA-LNPs) into lung epithelial cells. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine," said Safia Rizvi, CEO, CILA Therapeutics Share In preclinical studies, the CIL-Key™ platform (also referred to as CIL-0X in the grant) achieved up to a 430% increase in delivery of functionally intact RNA into human bronchial epithelial cells cultured at an air-liquid interface (ALI), demonstrating utility across multiple RNA-LNP formulations. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine,' said Safia Rizvi, CEO of CILA Therapeutics. CIL-Key™ is designed to enable efficient, localized intracellular delivery of RNA-based modalities while minimizing systemic exposure. The platform could offer significant advantages for companies developing inhaled RNA therapies and vaccines for a broad range of lung diseases, including Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), COPD and Pulmonary Fibrosis, as well as respiratory infections including influenza, RSV and COVID-19. Chronic pulmonary diseases affect more than 34 million people in the U.S. and more than 545 million globally. These often progressive, life-limiting conditions have a significant impact on quality of life and a high economic burden, creating an urgent demand for novel, effective and easy-to-administer treatments like those powered by CIL-Key™. About CILA Therapeutics CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients' daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA's pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases. Visit CILA is actively seeking strategic partnerships to expand the platform's application across diverse RNA-based pipelines for rare and common pulmonary indications.
Yahoo
3 hours ago
- Yahoo
RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List
PHILADELPHIA, August 14, 2025--(BUSINESS WIRE)--RAM Technologies, Inc., a leading technology enabled services provider to Medicare Advantage, Special Needs and Managed Medicaid health plans, has earned a place on the 2025 Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With three-year revenue growth of nearly 100%, this marks the company's ninth time on the list. The Inc. 5000 offers a data-driven look at the nation's most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Rankings are based on percentage revenue growth from 2021 to 2024, and RAM Technologies was honored for its exceptional growth and innovation. "It's an honor to once again be recognized on the Inc. 5000 list," said Robert Tulio, CEO of RAM Technologies. "Our growth is the result of a clear mission to equip government-sponsored health plans with software and services to operate efficiently and put members at the center of every decision. This achievement reflects the impact we're making in the healthcare industry, and our team's focus on innovation and quality." The company's sustained growth has been fueled by expanding relationships with health plans nationwide, a commitment to exceptional client service and the ability to provide BPaaS solutions that enhance outcomes for clients. RAM Technologies specializes in delivering purpose-built solutions for government-sponsored health plans. The company's core platform, HEALTHsuite Advantage, gives health plans added flexibility through the choice of SaaS and BPaaS deployment models. By combining software with expert implementation and support, RAM helps health plans reduce costs, streamline operations and improve member experiences. "Our solutions give health plans tools to operate more efficiently, deliver a better experience for members and ensure compliance with regulatory requirements," said Tulio. "We're proud to have achieved sustained growth in such a competitive market, and we remain focused on delivering solutions to help our clients succeed." For the full list, company profiles, and a searchable database by industry and location, visit: About RAM Technologies RAM Technologies is a leading provider of enterprise solutions for government-sponsored healthcare payers. For over 44 years RAM Technologies has led the way in the creation of comprehensive, end-to-end SaaS and BPaaS solutions for health plans administering Medicare Advantage, Managed Medicaid and Special Needs plans. Our deep understanding of Medicare and Medicaid guarantees seamless integration and operational ease, allowing health plan staff to focus on what matters most. To learn more about RAM Technologies visit View source version on Contacts Media Contact Robert Meyer, RAM Technologies, Inc., rmeyer@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data